BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ahn J, Lim JK, Lee HM, Lok AS, Nguyen M, Pan CQ, Mannalithara A, Te H, Reddy RK, Trinh H, Chu D, Tran T, Lau D, Leduc T, Min A, Le LT, Bae H, Van Tran S, Do S, Hann HL, Wong C, Han S, Pillai A, Park JS, Tong M, Scaglione S, Woog J, Kim RW. Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study. American Journal of Gastroenterology 2016;111:1297-304. [DOI: 10.1038/ajg.2016.257] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Min AD. Low-level viremia in hepatitis b patients on antiviral treatment: Can we ignore it?: Min. Hepatology 2017;66:312-4. [DOI: 10.1002/hep.29235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
2 Wu S, Zeng N, Sun F, Zhou J, Wu X, Sun Y, Wang B, Zhan S, Kong Y, Jia J, You H, Yang H. Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.02.040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Ha I, Chung JW, Jang ES, Jeong SH, Kim JW. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis. J Gastroenterol Hepatol 2020;35:1774-81. [PMID: 32154938 DOI: 10.1111/jgh.15031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
4 Dietrich CF, Teufel A, Sirlin CB, Dong Y. Surveillance of hepatocellular carcinoma by medical imaging. Quant Imaging Med Surg 2019;9:1904-10. [PMID: 31867241 DOI: 10.21037/qims.2019.10.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
5 Varbobitis I, Papatheodoridis GV. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. Clin Mol Hepatol. 2016;22:319-326. [PMID: 27729632 DOI: 10.3350/cmh.2016.0045] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
6 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065] [Cited by in Crossref: 365] [Cited by in F6Publishing: 367] [Article Influence: 91.3] [Reference Citation Analysis]
8 Rodríguez M, Buti M, Esteban R, Lens S, Prieto M, Suárez E, García-Samaniego J. Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). Gastroenterol Hepatol 2020;43:559-87. [PMID: 32778356 DOI: 10.1016/j.gastrohep.2020.03.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035. [PMID: 29877316 DOI: 10.1038/nrdp.2018.35] [Cited by in Crossref: 172] [Cited by in F6Publishing: 167] [Article Influence: 43.0] [Reference Citation Analysis]
10 Vo Quang E, Shimakawa Y, Nahon P. Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination. Liver Int 2021;41:915-27. [PMID: 33641230 DOI: 10.1111/liv.14843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, Lee SS, Han K, Nam CM, Park SH, Lee KH. Contrast-enhanced US with Perfluorobutane for Hepatocellular Carcinoma Surveillance: A Multicenter Diagnostic Trial (SCAN). Radiology 2019;292:638-46. [PMID: 31287387 DOI: 10.1148/radiol.2019190183] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
12 Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, Wang CC, Su WW, Chen MY, Peng CY, Chien RN, Huang YW, Wang HY, Lin CL, Yang SS, Chen TM, Mo LR, Hsu SJ, Tseng KC, Hsieh TY, Suk FM, Hu CT, Bair MJ, Liang CC, Lei YC, Tseng TC, Chen CL, Kao JH; C-TEAM study group and the Taiwan Liver Diseases Consortium. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36:1755-1764. [PMID: 27634134 DOI: 10.1111/liv.13253] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 18.0] [Reference Citation Analysis]
13 Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim YS. Risk of Hepatocellular Carcinoma in Patients Treated with Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study. JAMA Oncol. 2019;5:30-36. [PMID: 30267080 DOI: 10.1001/jamaoncol.2018.4070] [Cited by in Crossref: 108] [Cited by in F6Publishing: 99] [Article Influence: 36.0] [Reference Citation Analysis]
14 McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73 Suppl 1:4-13. [PMID: 32319693 DOI: 10.1002/hep.31288] [Cited by in Crossref: 61] [Cited by in F6Publishing: 77] [Article Influence: 30.5] [Reference Citation Analysis]
15 Alqahtani SA, Colombo M. Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma. Cells 2021;10:3091. [PMID: 34831314 DOI: 10.3390/cells10113091] [Reference Citation Analysis]
16 Ko KL, To WP, Mak LY, Seto WK, Ning Q, Fung J, Lai CL, Yuen MF. A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance. J Viral Hepat 2020;27:397-406. [PMID: 31755196 DOI: 10.1111/jvh.13237] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
17 Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:1039-1052. [PMID: 33007228 DOI: 10.1016/s2468-1253(20)30249-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
18 Watanabe M, Yokomori H, Takahashi Y, Okada T, Shibuya A, Koizumi W. Assessing the characteristics and feasibility of preventing early mortality in patients with hepatocellular carcinoma. Turk J Gastroenterol 2019;30:541-8. [PMID: 31144660 DOI: 10.5152/tjg.2019.18654] [Reference Citation Analysis]
19 Tseng CH, Tseng CM, Wu JL, Hsu YC, El-Serag HB. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review. J Gastroenterol Hepatol. 2020;35:1684-1693. [PMID: 32343431 DOI: 10.1111/jgh.15078] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
20 Shin JW, Jung SW, Lee SB, Lee BU, Park BR, Park EJ, Park NH. Medication Nonadherence Increases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated With Entecavir. Am J Gastroenterol 2018;113:998-1008. [PMID: 29880971 DOI: 10.1038/s41395-018-0093-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
21 Hsu YC, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB, Lee TY, Wu MS, Lin JT, Wong GL, Wu CY. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol. 2018;69:278-285. [PMID: 29551708 DOI: 10.1016/j.jhep.2018.02.032] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 13.3] [Reference Citation Analysis]
22 Kim MN, Hwang SG, Kim BK, Park JY, Kim DY, Han KH, Kim SU, Ahn SH. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. Gut Liver 2019;13:197-205. [PMID: 30602075 DOI: 10.5009/gnl18204] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
23 Li Q, Lu C, Li W, Huang Y, Chen L. Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B. Oncotarget. 2017;8:45768-45776. [PMID: 28514753 DOI: 10.18632/oncotarget.17470] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
24 El‐serag HB. Epidemiology of Hepatocellular Carcinoma. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 758-72. [DOI: 10.1002/9781119436812.ch59] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
25 Yip TC, Lai JC, Wong GL. Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same? J Gastroenterol 2020;55:1023-36. [PMID: 32974760 DOI: 10.1007/s00535-020-01726-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Sun Y, Zhang Y, Xu Y, Shu M, Bonroy K, Qiu H, Cai W. Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B. Epidemiol Infect 2019;147:e193. [PMID: 31364558 DOI: 10.1017/S0950268819000815] [Reference Citation Analysis]
27 Lee HW. [Long Term Efficacy of Antiviral Therapy: Mortality and Incidence of Hepatocellular Carcinoma]. Korean J Gastroenterol 2019;74:251-7. [PMID: 31765553 DOI: 10.4166/kjg.2019.74.5.251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Hsu Y, Ho H, Lee T, Huang Y, Wu M, Lin J, Wu C, El‐serag HB. Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir. J Viral Hepat 2018;25:543-51. [DOI: 10.1111/jvh.12832] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
29 Choi WM, Yip TC, Lim YS, Wong GL, Kim WR. Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. J Hepatol 2021:S0168-8278(21)02079-1. [PMID: 34592365 DOI: 10.1016/j.jhep.2021.09.017] [Reference Citation Analysis]
30 Zhang L, Zhang FK. Recent advances in assessment and treatment of chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2019; 27(4): 209-219 [DOI: 10.11569/wcjd.v27.i4.209] [Reference Citation Analysis]
31 Hsu YC, Tseng CH, Huang YT, Yang HI. Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective. Semin Liver Dis 2021;41:285-97. [PMID: 34161993 DOI: 10.1055/s-0041-1730924] [Reference Citation Analysis]